Amongst the largest Pharma companies in domestic market with Net Sales of INR 171.2bn with a strong brand portfolio. R&D; cost is in excess of 13% of Sales. Sales Mix: API - 7%, Domestic Formulations - 25%, DM Formulations - 62%, EM Formulations - 6%. Historically strong in anti-TB segment, has built expertise in fermentation based products and segments like Cephalosporins, Prils and Statins. Lupin is developing complex products in areas such as Opthalmology, Respiratory,...